Over the past few years, the global weight loss drug market has experienced unprecedented growth.

From Semaglutide igniting the GLP-1 era, to Tirzepatide driving the shift toward dual agonists, and now to the highly anticipated Retatrutide, the technological roadmap of anti-obesity therapies is undergoing a clear evolution.

For the industry, this not only means intensified competition among finished drugs, but also signals a new upgrade cycle across peptide APIs, CDMOs, modified intermediates, and the global pharmaceutical supply chain.

DengYueMed continues to closely follow how GLP-1 and next-generation multi-agonist therapies are reshaping the global pharmaceutical and peptide manufacturing landscape.

Phase One: Semaglutide Opened the GLP-1 Era

Semaglutide was the drug that truly demonstrated the commercial potential of GLP-1 therapies to the global market. Its primary mechanism focuses on appetite suppression, delayed gastric emptying, and improved glycemic control to support weight reduction.

As Wegovy and Ozempic rapidly expanded worldwide, GLP-1 drugs quickly became one of the hottest sectors in the pharmaceutical industry, directly driving:

● Growth in peptide API demand

● Global CDMO capacity expansion

● Increased demand for injectable manufacturing and cold-chain logistics

For the peptide industry, Semaglutide was not just a successful drug — it became the starting point of the global GLP-1 supply chain boom.

At the same time, it also reshaped how the industry viewed peptide therapeutics in metabolic disease treatment. Compared with traditional small-molecule drugs, peptide therapies began to demonstrate stronger long-term commercial value and broader market potential.

Phase Two: Tirzepatide Accelerated the Dual-Agonist Upgrade

As competition within the GLP-1 market intensified, relying solely on a single-target mechanism became increasingly insufficient for differentiation. This is where Tirzepatide pushed the industry into the dual-agonist era.

Compared with Semaglutide, Tirzepatide not only activates the GLP-1 receptor, but also incorporates GIP receptor agonism, forming a: GLP-1 + GIP dual mechanism.

This means the drug focuses not only on appetite control, but also further enhances metabolic regulation, including:

● Improved insulin sensitivity

● Enhanced energy metabolism

● Better lipid regulation

More importantly, Tirzepatide significantly increased the complexity of peptide therapeutics.

Compared with earlier GLP-1 drugs, it introduced greater manufacturing challenges across the supply chain, including longer peptide chains, more sophisticated long-acting modifications, and stricter purity requirements.

This is one of the key reasons why global peptide CDMOs have continued expanding capacity in recent years.

Many industry observers believe that Tirzepatide changed not only the obesity drug market itself, but also the global landscape of high-end peptide manufacturing.

Phase Three: Retatrutide Moves the Industry into the Triple-Agonist Era

If Tirzepatide represented the dual-agonist upgrade, then Retatrutide signals the industry's transition into the triple-agonist era.

Compared with Tirzepatide, Retatrutide further incorporates glucagon receptor agonism, creating a: GLP-1 + GIP + Glucagon triple-agonist mechanism.

The biggest shift in this design is that, beyond reducing caloric intake, Retatrutide further emphasizes:

● Energy expenditure

● Calorie burning

● Fat oxidation

● Whole-body metabolic regulation

In other words, the logic of weight loss therapies is evolving from simply “eating less” toward: “Eating less + stronger metabolic expenditure.”

At the same time, its technological complexity has increased significantly.

Because Retatrutide must balance activity across three different receptors simultaneously, its design must carefully optimize efficacy, stability, half-life, and long-acting performance. As a result, its industrial-scale manufacturing complexity is considerably higher than that of previous-generation GLP-1 therapies.

From Single Agonists to Triple Agonists: Comparing Three Generations of Weight Loss Drugs

Alongside the Drugs, the Global Peptide Supply Chain Is Also Upgrading

On the surface, the evolution of weight loss drugs may appear to be simply an increase in receptor targets. However, for the industry, the real transformation lies in the rapidly increasing complexity of peptide therapeutics.

From Semaglutide to Tirzepatide and now Retatrutide, the requirements for upstream raw materials and manufacturing technologies have risen substantially.

For example:

● More sophisticated non-natural amino acids

● More challenging fragment coupling processes

● More advanced long-acting modification technologies

● Stricter impurity control standards

These changes mean that global competition is no longer limited to finished pharmaceutical products. Increasingly, competition is centered around peptide API manufacturing capabilities, CDMO scale-up expertise, and global supply chain execution.

The Global Peptide Industry Is Entering a “High-Complexity Era”

As Eli Lilly and Company and Novo Nordisk continue advancing next-generation obesity therapies, the entire industry is shifting toward greater molecular and manufacturing complexity.

Global demand for:

● Long-chain peptides

● High-purity peptide APIs

● Non-natural amino acids

● Long-acting modification technologies

is growing rapidly.

At the same time, China’s peptide manufacturing capabilities are playing an increasingly important role within the global supply chain.

Particularly in areas such as:

● Peptide API manufacturing

● Modified amino acids

● Long-acting formulation technologies

● Process scale-up

● Global supply chain delivery

China’s competitiveness within the peptide supply chain continues to strengthen.

From Drug Competition to Global Supply Chain Competition

From Semaglutide to Tirzepatide and now Retatrutide, the evolution of weight loss therapies is becoming increasingly clear: Single agonist → Dual agonist → Triple agonist.

Behind this transition, the global peptide industry is simultaneously undergoing a major upgrade.

Over the next several years, as next-generation obesity therapies continue advancing, peptide APIs, CDMOs, and key modified raw materials may enter another major growth cycle.

As a China pharmaceutical distributor and peptide supply chain service provider, DengYueMed will continue monitoring the development of GLP-1 therapies, multi-agonist drugs, and next-generation peptide therapeutics, while supporting global customers with APIs, pharmaceutical intermediates, peptide raw materials, and international supply chain solutions.